| Literature DB >> 34181595 |
Luiz H Geraldo1, Yunling Xu1, Laurent Jacob1, Laurence Pibouin-Fragner1, Rohit Rao2, Nawal Maïssa3, Maite Verreault4, Nolwenn Lemaire4, Camille Knosp1, Corinne Lesaffre1, Thomas Daubon5, Joost Dejaegher6, Lien Solie7, Justine Rudewicz8, Thomas Viel1, Bertrand Tavitian1, Steven De Vleeschouwer6, Marc Sanson4, Andreas Bikfalvi8, Ahmed Idbaih4, Qing Richard Lu2, Flavia Rs Lima9, Jean-Leon Thomas4, Anne Eichmann10, Thomas Mathivet1.
Abstract
SLIT2 is a secreted polypeptide that guides migration of cells expressing ROBO1&2 receptors. Herein, we investigated SLIT2/ROBO signaling effects in gliomas. In patients with glioblastoma (GBM), SLIT2 expression increased with malignant progression and correlated with poor survival and immunosuppression. Knockdown of SLIT2 in mouse glioma cells and patient derived GBM xenografts reduced tumor growth and rendered tumors sensitive to immunotherapy. Tumor cell SLIT2 knockdown inhibited macrophage invasion and promoted a cytotoxic gene expression profile, which improved tumor vessel function and enhanced efficacy of chemotherapy and immunotherapy. Mechanistically, SLIT2 promoted microglia/macrophage chemotaxis and tumor-supportive polarization via ROBO1&2-mediated PI3Kgamma activation. Macrophage Robo1&2 deletion and systemic SLIT2 trap delivery mimicked SLIT2 knockdown effects on tumor growth and the tumor microenvironment (TME), revealing SLIT2 signaling through macrophage ROBOs as a potentially novel regulator of the GBM microenvironment and immunotherapeutic target for brain tumors.Entities:
Keywords: Brain cancer; Immunotherapy; Macrophages; Oncology; Vascular Biology
Year: 2021 PMID: 34181595 DOI: 10.1172/JCI141083
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808